This randomized, controlled, multicenter and blind study compared the second generation of bio-absorbable stent platform with the everolimus-eluting Xience. 501 patients were randomized 2: 1 (Absorb / Xience) with de novo lesions in native coronary arteries with a reference diameter between 2.25 and 3.8 mm estimated by quantitative angiography. All the patients underwent IVUS and virtual histology in the index procedure (pre and post implant) and 2-year angiographic follow-up. The final rate of thrombosis was 0.6% for the Absorb group and 0% for Xience. At one year clinical events (cardiac death, infarct-related to vessel and lesion revascularization) were similar between the two devices (Absorb 4.8% versus Xience 3%, p = 0.35).
3_patrick_serruys
Patrick W. Serruys
2014-09-15
Original title: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease.